isophosphamide mustard has been researched along with azomycin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, X; Duan, JX; Jiao, H; Jung, D; Lin, L; Matteucci, M | 1 |
| Constantinidou, A; van der Graaf, WTA | 1 |
2 other study(ies) available for isophosphamide mustard and azomycin
| Article | Year |
|---|---|
Pharmacokinetics of TH-302: a hypoxically activated prodrug of bromo-isophosphoramide mustard in mice, rats, dogs and monkeys.
Topics: Administration, Oral; Animals; Dogs; Drug Evaluation, Preclinical; Female; Half-Life; Humans; Hypoxia; Infusions, Intravenous; Injections, Intraperitoneal; Injections, Intravenous; Macaca fascicularis; Male; Mice; Mice, Inbred Strains; Mice, Nude; Molecular Structure; Nitroimidazoles; Phosphoramide Mustards; Predictive Value of Tests; Prodrugs; Rats; Rats, Sprague-Dawley; Species Specificity; Tissue Distribution | 2012 |
The fate of new fosfamides in phase III studies in advanced soft tissue sarcoma.
Topics: Antineoplastic Agents, Alkylating; Clinical Trials, Phase III as Topic; Evidence-Based Medicine; Humans; Neoplasm Staging; Nitroimidazoles; Phosphoramide Mustards; Randomized Controlled Trials as Topic; Research Design; Risk Factors; Sarcoma; Soft Tissue Neoplasms; Survival Analysis; Time Factors; Treatment Outcome | 2017 |